Edgestream Partners L.P. bought a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 82,398 shares of the biopharmaceutical company’s stock, valued at approximately $9,999,000.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Banco Santander S.A. increased its stake in shares of Incyte by 59.1% during the 3rd quarter. Banco Santander S.A. now owns 11,532 shares of the biopharmaceutical company’s stock worth $1,399,000 after purchasing an additional 4,282 shares during the last quarter. Teachers Retirement System of The State of Kentucky lifted its stake in shares of Incyte by 47.5% in the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 362,550 shares of the biopharmaceutical company’s stock valued at $43,996,000 after purchasing an additional 116,800 shares during the last quarter. Hantz Financial Services Inc. lifted its stake in shares of Incyte by 6.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,446 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 92 shares during the last quarter. Ground Swell Capital LLC acquired a new stake in shares of Incyte in the 3rd quarter valued at $564,000. Finally, Bellwether Advisors LLC bought a new stake in Incyte in the third quarter worth $1,201,000. 96.97% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Incyte
In other news, CMO Steven H. Stein sold 240,193 shares of Incyte stock in a transaction dated Friday, November 6th. The stock was sold at an average price of $118.39, for a total value of $28,436,449.27. Following the transaction, the chief marketing officer directly owned 30,916 shares in the company, valued at approximately $3,660,145.24. The trade was a 88.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of Incyte stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total value of $72,565.60. Following the completion of the transaction, the insider owned 21,126 shares in the company, valued at $2,513,148.96. The trade was a 2.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 254,246 shares of company stock worth $30,162,968 over the last ninety days. Company insiders own 16.20% of the company’s stock.
Wall Street Analyst Weigh In
Several equities analysts have commented on INCY shares. Royal Bank Of Canada increased their target price on shares of Incyte from $114.00 to $117.00 and gave the stock a “sector perform” rating in a research report on Friday, October 30th. Truist Financial raised their target price on Incyte from $105.00 to $115.00 and gave the company a “hold” rating in a report on Wednesday, October 14th. Oppenheimer set a $152.00 price target on Incyte in a research report on Tuesday, October 27th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a research note on Friday, September 11th. Finally, Citigroup reissued a “buy” rating on shares of Incyte in a report on Monday, August 3rd. Eleven analysts have rated the stock with a Buy rating and fourteen have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $132.86.
Read Our Latest Report on INCY
Incyte Trading Down 0.6%
Shares of Incyte stock opened at $120.27 on Tuesday. The firm has a fifty day simple moving average of $119.05 and a 200-day simple moving average of $109.05. Incyte Corporation has a 1-year low of $89.25 and a 1-year high of $132.60. The stock has a market capitalization of $24.51 billion, a price-to-earnings ratio of 57.41, a PEG ratio of 4.43 and a beta of 0.78.
Incyte (NASDAQ:INCY – Get Free Report) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. The business had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.46 billion. Incyte had a net margin of 6.71% and a return on equity of 7.92%. Incyte’s revenue was up 14.0% compared to the same quarter last year. During the same period last year, the business posted $2.26 EPS. As a group, research analysts predict that Incyte Corporation will post 2.24 earnings per share for the current year.
Incyte Company Profile
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Featured Articles
- Five stocks we like better than Incyte
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
